The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
about
Biologics in oral medicine: oral Crohn's disease and orofacial granulomatosisBiological treatment of Crohn's disease.Management of active Crohn disease.Differential effect of genetic burden on disease phenotypes in Crohn's disease and ulcerative colitis: analysis of a North American cohort.Risk of infections associated with biological treatment in inflammatory bowel disease.Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patientsCurrent opinion on treatment of inflammatory bowel disease in pregnant women.Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease.Cardiac Tamponade as a Presenting Manifestation of Infliximab-Induced Lupus in Patient Treated for Crohn's Disease.Second Korean guidelines for the management of ulcerative colitis.A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy.Biologics in oral medicine: principles of use and practical considerations.Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update.Infectious and malignant complications of TNF inhibitor therapy in IBD.Drug safety evaluation of certolizumab pegol.Inflammatory bowel disease and demyelination: more than just a coincidence?Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review.The role and advances of immunomodulator therapy for inflammatory bowel disease.Biological therapy for ulcerative colitis.Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.Early histological findings may predict the clinical phenotype in Crohn's colitis.Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.Risk of lymphoma in patients with inflammatory bowel disease.Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening.The safety of treatments used in pyoderma gangrenosum.Enteropathogenic viruses: triggers for exacerbation in IBD? A prospective cohort study using real-time quantitative polymerase chain reaction.Meta-analysis: rapid infliximab infusions are safe.IBD: Step-up vs top-down therapy for Crohn's disease: medicine vs surgery.Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication).
P2860
Q28261955-3AF47E0A-18F8-4915-81CE-52DCDDB3791EQ33354991-7D4796AC-F195-47E7-9DBA-8001D2F4E48CQ34345967-CD0F9B94-ACFE-48A2-973C-88CEB7EA82F5Q34475941-54FBBB17-60BD-4A41-AB74-4CE6E6DFE0E3Q34552028-8BEADB7F-9268-41C8-8844-321D58599A51Q35811221-D48EF70D-8CA5-4542-8AA6-D9953EF47D86Q36524821-D8B24D7D-73EA-4487-96BA-971A155670C6Q36692197-CDC26399-CAE0-4FF3-B119-0397B5399BDDQ37467519-8E166C41-425E-426C-BF1F-7F135C3F1158Q37593973-0CBF7EDD-436C-4B65-AA88-A69B54966152Q37662503-D9F1DC8F-4769-4DD2-966E-9842A7A0377EQ37678199-5275DD9F-0DA6-4BDD-B39E-B9A6E5AFF304Q37993932-C58906B4-1D8B-43CC-868D-77B3FACE5A32Q38068963-FF6B151A-0AB7-41C7-B910-5D7EF1384417Q38138343-B8FFEDC2-424A-4430-A215-663E32180D90Q38155217-BBDD3A08-8C17-48A9-AE22-9A42E4FC193FQ38184633-6A7A34E1-EAE1-41BD-A5BF-93BF0C2568CAQ38201788-88099CA6-D0F9-408E-A8F0-84B33E2CF9BAQ38237701-9CE98AE3-2417-41FB-9E10-E3B886F036B0Q38262662-27AB9205-BFA7-4606-BE6C-8C7BFD9A6A82Q38317338-87AB3148-656D-48FC-9B00-899345C04E96Q38364465-D4780D9D-5F06-4657-8A01-CE86B554F262Q38563075-9F91BC31-348D-40EA-A152-14FEF01D0D8BQ38621241-CB9918E4-7CAB-40E8-90C6-6A6AB20968B3Q39435409-4B02785B-4C6C-49EE-938E-90FF425317D5Q41019683-2B492F82-F697-4A03-B24E-CC50DAE16CD4Q42238439-66ABE241-3AD1-42E4-B5C2-DED5840A7875Q47641664-C28EB3E6-08DA-41FC-8527-363B2D1DA9C7Q47896239-F3BB8C23-E6B5-4FFF-B1CB-01D19B35D4F9Q48215570-E0787553-1505-497C-B585-2FF618BE591BQ50091514-B41753FF-B892-4C68-9D22-F19FB4B569B9Q54216562-3EDFF130-1950-44AA-8F73-B9DEDDFED368
P2860
The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The London position statement ...... Colitis Organisation: safety.
@en
The London position statement ...... Colitis Organisation: safety.
@nl
type
label
The London position statement ...... Colitis Organisation: safety.
@en
The London position statement ...... Colitis Organisation: safety.
@nl
prefLabel
The London position statement ...... Colitis Organisation: safety.
@en
The London position statement ...... Colitis Organisation: safety.
@nl
P2093
P2860
P50
P356
P1476
The London position statement ...... Colitis Organisation: safety.
@en
P2093
Corey A Siegel
Gary R Lichtenstein
James D Lewis
Qin Ouyang
Simon P L Travis
P2860
P2888
P304
1594-602; quiz 1593, 1603
P356
10.1038/AJG.2011.211
P407
P577
2011-08-16T00:00:00Z
P5875
P6179
1034769169